Oxidative stress and bronchopulmonary dysplasia
- PMID: 24027702
- PMCID: PMC3762019
- DOI: 10.4103/2249-4847.101683
Oxidative stress and bronchopulmonary dysplasia
Abstract
Bronchopulmonary dysplasia (BPD) is the major cause of pulmonary disease in infants. The pathophysiology and management of BPD changed with the improvement of neonatal intensive care unit (NICU) management and with the increase of survival rates. Despite the improvements made, BPD is still a public health concern, resulting in frequent hospitalizations with high rates of mortality, impaired weight and height growth, and neurodevelopmental disorders. Lung injury in the neonatal period has multiple etiologic factors - genetic, hemodynamic, metabolic, nutritional, mechanical, and infectious mechanisms - act in a cumulative and synergic way. Free radical (FR) generation is largely recognized as the major cause of lung damage. Oxidative stress (OS) is the final common endpoint for a complex convergence of events, some genetically determined and some triggered by in utero stressors. Inflammatory placental disorders and chorioamnionitis also play an important role due to the coexistence of inflammatory and oxidative lesions. In addition, the contribution of airway inflammation has been extensively studied. The link between inflammation and OS injury involves the direct activation of inflammatory cells, especially granulocytes, which potentiates the inflammatory reaction. Individualized interventions to support ventilation, minimize oxygen exposure, minimize apnea, and encourage growth should decrease both the frequency and severity of BPD. Future perspectives suggest supplementation with enzymatic and/or non-enzymatic antioxidants. The use of antioxidants in preterm newborns particularly exposed to OS and at risk for BPD represents a logical strategy to ameliorate FRs injury, but further studies are needed to support this hypothesis.
Keywords: Bronchopulmonary dysplasia; oxidative stress; preterm newborns.
Conflict of interest statement
References
-
- Jobe AJ. The new BPD: An arrest of lung development. Pediatr Res. 1999;46:641–3. - PubMed
-
- Northway WH, Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276:357–68. - PubMed
-
- Groothuis JR, Makari D. Definition and outpatient management of the very low-birth-weight infant with bronchopulmonary dysplasia. Adv Ther. 2012;29:297–311. Epub 2012 Apr 16. - PubMed
-
- Perrone S, Tataranno ML, Negro S, Longini M, Marzocchi B, Proietti F, et al. Early identification of the risk for free radical related diseases in preterm newborns. Early Hum Dev. 2010;86:241–4. - PubMed
-
- Ballard PL, Truog WE, Merrill JD, Gow A, Posencheg M, Golombek SG, et al. Plasma biomarkers of oxidative stress: Relationship to lung disease and inhaled nitric oxide therapy in premature infants. Pediatrics. 2008;121:555–61. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
